olaparib
New Indication Granted for Lynparza for BRCA-mutated mCRPC
The FDA granted a new indication for Lynparza with abiraterone and a steroid for adult patients with deleterious or ...
JUNE 2, 2023
Olaparib Now Indicated for Adjuvant Treatment of High-Risk Early Breast Cancer
The FDA approved olaparib (Lynparza, AstraZeneca) as an adjuvant treatment for adults with germline BRCA-mutated, ...
MARCH 17, 2022
Lynparza Approved for Use in HRR-Mutated mCRPC
The FDA approved olaparib (Lynparza, AstraZeneca) for the treatment of adults with deleterious or suspected ...
MAY 28, 2020
Lynparza Approved to Treat BRCA-Mutated Metastatic Breast Cancer
The FDA expanded the approved use of olaparib (Lynparza, AstraZeneca) to include the treatment of patients with ...
JANUARY 14, 2018
Load more